200 related articles for article (PubMed ID: 21792197)
41. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
[TBL] [Abstract][Full Text] [Related]
42. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
[TBL] [Abstract][Full Text] [Related]
43. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R
Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578
[TBL] [Abstract][Full Text] [Related]
44. Advanced anal squamous cell carcinoma -- radiotherapy or surgery?
Smigielski J; Rychter A; Fijuth J; Brocki M
Chirurgia (Bucur); 2012; 107(5):626-30. PubMed ID: 23116837
[TBL] [Abstract][Full Text] [Related]
45. SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma.
Miyawaki A; Ikeda R; Hijioka H; Ishida T; Ushiyama M; Nozoe E; Nakamura N
Oncol Rep; 2010 May; 23(5):1205-12. PubMed ID: 20372831
[TBL] [Abstract][Full Text] [Related]
46. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
[TBL] [Abstract][Full Text] [Related]
47. (18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer.
Jingu K; Kaneta T; Nemoto K; Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Takai Y; Takahashi S; Yamada S
Int J Clin Oncol; 2010 Apr; 15(2):184-90. PubMed ID: 20217449
[TBL] [Abstract][Full Text] [Related]
48. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients.
Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP
Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888
[TBL] [Abstract][Full Text] [Related]
49. Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT.
Katahira-Suzuki R; Hata M; Tateishi U; Taguchi T; Takano S; Omura-Minamisawa M; Inoue T
Ann Nucl Med; 2015 Jan; 29(1):37-45. PubMed ID: 25228378
[TBL] [Abstract][Full Text] [Related]
50. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
[TBL] [Abstract][Full Text] [Related]
51. Textural features of cervical cancers on FDG-PET/CT associate with survival and local relapse in patients treated with definitive chemoradiotherapy.
Chen SW; Shen WC; Hsieh TC; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yen KY; Kao CH
Sci Rep; 2018 Aug; 8(1):11859. PubMed ID: 30089896
[TBL] [Abstract][Full Text] [Related]
52. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
53. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study.
Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R
Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262
[No Abstract] [Full Text] [Related]
54. Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma.
Giannatempo P; Alessi A; Miceli R; Raggi D; Farè E; Nicolai N; Serafini G; Padovano B; Piva L; Biasoni D; Torelli T; Catanzaro M; Stagni S; Maffezzini M; Mariani L; Gianni AM; Sonpavde G; Salvioni R; Necchi A; Crippa F
Clin Genitourin Cancer; 2014 Dec; 12(6):433-9. PubMed ID: 24787972
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
[TBL] [Abstract][Full Text] [Related]
56. Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patients.
Slim N; Passoni P; Incerti E; Tummineri R; Gumina C; Cattaneo GM; De Nardi P; Canevari C; Fiorino C; Ronzoni M; Tamburini AM; Burgio V; Gianolli L; Di Muzio N
Sci Rep; 2020 Sep; 10(1):14613. PubMed ID: 32884036
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of post-treatment ¹⁸F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis.
Kim YJ; Han S; Kim YS; Nam JH
J Gynecol Oncol; 2019 Sep; 30(5):e66. PubMed ID: 31328452
[TBL] [Abstract][Full Text] [Related]
58. Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?
Sabbagh A; Jacobs C; Cooke R; Chu KY; Ng SM; Strauss VY; Virdee PS; Hawkins MA; Aznar MC; Muirhead R
Clin Oncol (R Coll Radiol); 2019 Feb; 31(2):72-80. PubMed ID: 30583927
[TBL] [Abstract][Full Text] [Related]
59. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
[TBL] [Abstract][Full Text] [Related]
60. Lymph node standardized uptake values at pre-treatment
Jeong Y; Baek S; Park JW; Joo JH; Kim JS; Lee SW
Br J Radiol; 2017 Mar; 90(1071):20160239. PubMed ID: 28008776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]